Retinal Vascular Occlusion after COVID-19 Vaccination: More Coincidence than Causal Relationship? Data from a Retrospective Multicentre Study.
COVID-19
SARS-CoV-2
anterior ischaemic optic neuropathy
infection
retinal artery occlusion
retinal vein occlusion
vaccination
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
30 Aug 2022
30 Aug 2022
Historique:
received:
17
07
2022
revised:
23
08
2022
accepted:
26
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
To investigate whether vaccination against SARS-CoV-2 is associated with the onset of retinal vascular occlusive disease (RVOD). In this multicentre study, data from patients with central and branch retinal vein occlusion (CRVO and BRVO), central and branch retinal artery occlusion (CRAO and BRAO), and anterior ischaemic optic neuropathy (AION) were retrospectively collected during a 2-month index period (1 June-31 July 2021) according to a defined protocol. The relation to any previous vaccination was documented for the consecutive case series. Numbers of RVOD and COVID-19 vaccination were investigated in a case-by-case analysis. A case-control study using age- and sex-matched controls from the general population (study participants from the Gutenberg Health Study) and an adjusted conditional logistic regression analysis was conducted. Four hundred and twenty-one subjects presenting during the index period (61 days) were enrolled: one hundred and twenty-one patients with CRVO, seventy-five with BRVO, fifty-six with CRAO, sixty-five with BRAO, and one hundred and four with AION. Three hundred and thirty-two (78.9%) patients had been vaccinated before the onset of RVOD. The vaccines given were BNT162b2/BioNTech/Pfizer ( To date, there has been no evidence of any association between SARS-CoV-2 vaccination and a higher RVOD risk.
Sections du résumé
BACKGROUND
BACKGROUND
To investigate whether vaccination against SARS-CoV-2 is associated with the onset of retinal vascular occlusive disease (RVOD).
METHODS
METHODS
In this multicentre study, data from patients with central and branch retinal vein occlusion (CRVO and BRVO), central and branch retinal artery occlusion (CRAO and BRAO), and anterior ischaemic optic neuropathy (AION) were retrospectively collected during a 2-month index period (1 June-31 July 2021) according to a defined protocol. The relation to any previous vaccination was documented for the consecutive case series. Numbers of RVOD and COVID-19 vaccination were investigated in a case-by-case analysis. A case-control study using age- and sex-matched controls from the general population (study participants from the Gutenberg Health Study) and an adjusted conditional logistic regression analysis was conducted.
RESULTS
RESULTS
Four hundred and twenty-one subjects presenting during the index period (61 days) were enrolled: one hundred and twenty-one patients with CRVO, seventy-five with BRVO, fifty-six with CRAO, sixty-five with BRAO, and one hundred and four with AION. Three hundred and thirty-two (78.9%) patients had been vaccinated before the onset of RVOD. The vaccines given were BNT162b2/BioNTech/Pfizer (
CONCLUSIONS
CONCLUSIONS
To date, there has been no evidence of any association between SARS-CoV-2 vaccination and a higher RVOD risk.
Identifiants
pubmed: 36079030
pii: jcm11175101
doi: 10.3390/jcm11175101
pmc: PMC9457026
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
PLoS One. 2017 Jun 1;12(6):e0177663
pubmed: 28570629
Ocul Immunol Inflamm. 2021 Aug 18;29(6):1216-1224
pubmed: 34559576
Indian J Ophthalmol. 2021 Dec;69(12):3398-3420
pubmed: 34826968
Lancet. 2020 May 16;395(10236):e87-e88
pubmed: 32423587
Can J Ophthalmol. 2021 Feb;56(1):24-30
pubmed: 33249111
BMJ. 2012 Nov 30;345:e7885
pubmed: 23204001
Ophthalmic Surg Lasers Imaging Retina. 2022 Jan;53(1):22-30
pubmed: 34982005
Ophthalmologe. 2021 Jul;118(Suppl 2):166-175
pubmed: 34086070
Drug Saf. 2022 Feb;45(2):137-144
pubmed: 35064899
Lancet Respir Med. 2022 Jul;10(7):679-688
pubmed: 35421376
Arq Bras Oftalmol. 2022 Jan 21;85(2):158-165
pubmed: 35298583
Dtsch Arztebl Int. 2016 Dec 2;113(48):809-815
pubmed: 28073425
Ann Neurol. 2021 Oct;90(4):627-639
pubmed: 34288044
Herz. 2015 Feb;40(1):8-15
pubmed: 25604071
Int Med Case Rep J. 2022 Jan 16;15:7-14
pubmed: 35079224
Drug Saf. 2006;29(5):385-96
pubmed: 16689555
Acta Ophthalmol. 2020 Feb 6;:
pubmed: 32026572
BMC Cardiovasc Disord. 2018 May 10;18(1):91
pubmed: 29743025
Ophthalmology. 2020 Feb;127(2):P288-P320
pubmed: 31757503
J Thromb Thrombolysis. 2020 Jul;50(1):54-67
pubmed: 32415579
J Clin Med. 2022 Jun 09;11(12):
pubmed: 35743388
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Nov;61(11):1365-1376
pubmed: 30215104
Vaccines (Basel). 2021 Nov 17;9(11):
pubmed: 34835280
Ann Hematol. 2020 Aug;99(8):1701-1707
pubmed: 32583086
Ophthalmology. 2020 Feb;127(2):P259-P287
pubmed: 31757501
Eye Brain. 2017 Sep 27;9:23-28
pubmed: 29033621
Lancet Haematol. 2020 Jun;7(6):e438-e440
pubmed: 32407672
Front Med (Lausanne). 2021 Jul 09;8:676554
pubmed: 34307408
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Ophthalmologica. 2019;242(3):123-162
pubmed: 31412332
Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2243-2249
pubmed: 33961108
Intern Emerg Med. 2020 Nov;15(8):1375-1387
pubmed: 32653981
PLoS One. 2017 Aug 3;12(8):e0181766
pubmed: 28771491
Medicine (Baltimore). 2021 Dec 30;100(52):e28424
pubmed: 34967379
Clin Res Cardiol. 2022 Mar;111(3):272-283
pubmed: 34169342
J Glob Health. 2019 Jun;9(1):010427
pubmed: 31131101
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Jun;55(6-7):824-9
pubmed: 22736163
Ophthalmology. 2015 Sep;122(9):1881-8
pubmed: 26231133